Speakers

Expand/Collapse

Eleonora Lad
Associate Professor of Ophthalmology, Director of Grading Duke Reading Center
Duke University

Eleonora (Nora) Lad, MD, PhD is a clinician scientist and retinal ophthalmologist with the primary goal of developing novel strategies for early diagnosis and treatment of age-related macular degeneration (AMD). Dr. Lad’s academic career goal is to translate her doctoral training in neuroscience on neuroregenerative strategies for Parkinson’s disease into developing innovative diagnostic and therapeutic approaches for AMD. Her research interests are the following: 1)  visual function testing in dry AMD with the goal of establishing functional endpoints for clinical studies in earlier stages of AMD 2) investigating the role of neuroinflammation (macrophages/microglia) and abnormal protein aggregates in the pathogenesis of AMD and developing relevant treatments 3) elucidating the use of novel retinal imaging biomarkers for early diagnosis of AMD, including through use of artificial intelligence (machine and deep learning). Dr. Lad has served as the primary investigator for investigator-initiated and phase 1 through 3 clinical trials at the Duke Eye Center and as director of grading for retina clinical trials at Duke Reading Center.  Currently, she is also fulfilling the role of international lead PI for the Apellis phase 3 OAKS study for geographic atrophy secondary to AMD.  Dr. Lad advises industry sponsors on novel, approvable visual function assessments in the context of clinical trials for retinal disease, with particular expertise in dry AMD (intermediate and GA) and retinal degeneration/retinitis pigmentosa.  She has assisted with clinical trial protocol design, site certification, data analysis, and presentations to the regulatory agencies (US Food and Drug Adminitration and European Medicine Agency). Dr. Lad was awarded the VA Clinical Science Research and Development I01 Merit Award, the Mentored Patient-Oriented Research Career Development (K23) Award from the National Eye Institute, the 2016 ARVO/Alcon Early Career Clinician-Scientist Research Award, Research to Prevent Blindness Ernest & Elizabeth Althouse Special Scholar Award, Duke Health Scholar, and a number of foundation grants.  She is a member of Macula Society, Retina Society, Ryan (previously Beckman) Initiative for Macular Research, American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, International Society for Eye Research, Society of Heed Fellows, Society for Neuroscience and American Society for Neural Therapy and Repair.

Day One

Wednesday, October 28, 2020

4:40 pm | Establishing Correlations Between Functional outcomes, Imaging- and Blood-Based Biomarkers in Nonexudative AMD: Lessons Learned and Regulatory Implications

5:40 pm | Live Presenter Q&A

SriniVas Sadda
President and Chief Scientific Officer, Doheny Eye Institute; Professor of Ophthalmology
Doheny Eye Institute, UCLA

Day One

Wednesday, October 28, 2020

4:00 pm | Patient Selection and Monitoring for Efficacy in Dry AMD trials

Clark Tedford
Co-Founder
LumiThera

Day Two

Thursday, October 29, 2020

10:50 am | Photobiomodulation as a Novel Treatment for Dry AMD Patients

11:50 am | Live Presenter Q&A

Simon Kaja
Chief Scientific Officer & Vice-President, Americas
Experimentica

Day One

Wednesday, October 28, 2020

10:00 am | Preclinical Models for Drug Discovery in Dry AMD

Pooya Hemami
Healthcare & Supervisory Analyst
Edison Group

Day Two

Thursday, October 29, 2020

3:30 pm | Panel Discussion: Developing, Commercializing & Delivering Dry AMD Therapeutics into the Hands of Physicians & Patients in Need

Gabrielle DeBartolomeo
Clinical Trial Scientist
Alkeus Pharmaceuticals

Day One

Wednesday, October 28, 2020

9:15 am | Topics to be discussed:

Leonide Saad
President & CEO
Alkeus Pharmaceuticals, Inc.

Day Two

Thursday, October 29, 2020

3:30 pm | Panel Discussion: Developing, Commercializing & Delivering Dry AMD Therapeutics into the Hands of Physicians & Patients in Need

9:40 am | Live Presenter Q&A

9:00 am | Slow Progression of Dry AMD: Small Molecule Approaches

Lukas Scheibler
Chief Innovation Officer
Apellis Pharmaceuticals

Day One

Wednesday, October 28, 2020

2:50 pm | Live Presenter Q&A

1:50 pm | Advancing the Targeted C3 Therapy, Pegcetacoplan, for the Treatment of Geographic Atrophy

Mark Shearman
Chief Scientific Officer
Applied Genetic Technologies Corporation

Day One

Wednesday, October 28, 2020

9:15 am | Topics to be discussed:

Dang Dao
Director - Research
Astellas Pharma Inc

Day Two

Thursday, October 29, 2020

3:10 pm | Live Presenter Q&A

2:30 pm | Cell-based Therapies for Blinding Diseases

Victor Chong
Global Head of Medicine, Retinal Health
Boehringer Ingelheim International GmbH

Day One

Wednesday, October 28, 2020

1:40 pm | Live Presenter Q&A

1:00 pm | Neuroprotection in Geographic Atrophy

Konstantin Petruhkin
Associate Professor
Columbia University

Catherine Bowes Rickman
Professor of Ophthalmology
Duke University

Day One

Wednesday, October 28, 2020

2:50 pm | Live Presenter Q&A

2:30 pm | Re-imagining complement-based therapies for AMD

Christopher Brittain
Vice President & Global Head of Ophthalmology Product Development
Genentech

Day One

Wednesday, October 28, 2020

9:15 am | Topics to be discussed:

Kourous Rezaei
Chief Medical Officer
IVERIC Bio

Day One

Wednesday, October 28, 2020

2:50 pm | Live Presenter Q&A

2:10 pm | Zimura, Novel Complement C5 Inhibitor, Significantly Reduces the Mean Rate of Geographic Atrophy Growth in a Phase 3 Clinical Trial

9:15 am | Topics to be discussed:

Brian M. Culley
Chief Executive Officer
Lineage Cell Therapeutics, Inc

Day One

Wednesday, October 28, 2020

12:00 pm | Live Presenter Q&A

11:00 am | OpRegen, an RPE Transplant for the Treatment of Dry AMD

Day Two

Thursday, October 29, 2020

3:30 pm | Panel Discussion: Developing, Commercializing & Delivering Dry AMD Therapeutics into the Hands of Physicians & Patients in Need

Jeffrey Stern
co-Chief Executive Officer
Neural Stem Cell Institute & Luxa Biotechnology

Day One

Wednesday, October 28, 2020

12:00 pm | Live Presenter Q&A

11:40 am | Adult RPE Stem Cell Transplantation as Therapy for dry AMD

Kapil Bharti
Senior Investigator
National Institutes of Health

Day Two

Thursday, October 29, 2020

3:10 pm | Live Presenter Q&A

2:50 pm | Advanced Cell-based Therapies for Macular Degeneration

Qian Huang
Head of Ocular Inflammation, Ophthalmology
Novartis

Day Two

Thursday, October 29, 2020

1:40 pm | Live Presenter Q&A

1:00 pm | Targeting Innate Immune Pathways in Intermediate AMD

Stephen Poor
Director & Head of Retinal Pharmacology Unit & Imaging Technologies Team
Novartis

Day One

Wednesday, October 28, 2020

1:40 pm | Live Presenter Q&A

1:20 pm | Analysis of Complement in of Donor/Post-Mortem Eyes with and Without Age-Related Macular Degeneration (Amd), Implications for Future Intermediate Amd or Geographic Atrophy (Ga) Clinical Trials

Jeffrey S. Heier
CO-President & Medical Director
Ophthalmic Consultants of Boston

Day One

Wednesday, October 28, 2020

9:15 am | Topics to be discussed:

9:00 am | Setting the Scene: An analysis of the Challenges Facing Dry AMD Therapeutics Developers and patients

Joshua Dunaief
Adele Niessen Professor of Ophthalmology Scheie Eye Institute
University of Pennsylvania

Day Two

Thursday, October 29, 2020

11:50 am | Live Presenter Q&A

11:30 am | Targeting Iron Induced Oxidative Stress and BRB Permeability in Dry AMD

Lloyd Diamond
Chief Executive Officer
Pixium Vision

Day Two

Thursday, October 29, 2020

12:20 pm | Live Presenter Q&A

Jane S. Lebkowski
President
Regenerative Patch Technologies

Day One

Wednesday, October 28, 2020

11:20 am | Development of a Composite RPE Cell-Ultrathin Membrane Implant for the Treatment of the Dry Form of Age-Related Macular Degeneration

12:00 pm | Live Presenter Q&A

Karl G. Csaky
T. Boone Pickens Director, Clinical Center of Innovation for AMD, Chief Executive and Medical Officer
Retina Foundation of the Southwest

Day Two

Thursday, October 29, 2020

3:30 pm | Panel Discussion: Developing, Commercializing & Delivering Dry AMD Therapeutics into the Hands of Physicians & Patients in Need

11:50 am | Live Presenter Q&A

11:10 am | Targeting Mitochondrial Oxidative Stress: Getting Drugs to the Retinal Tissue Mitochondria in Dry AMD

Reenie McCarthy
Director
President & Chief Executive Officer Stealth BioTherapeutics Inc

Day One

Wednesday, October 28, 2020

3:40 pm | Elamipretide, a Mitochondrial-Targeted Drug, in the Treatment of Dry AMD

5:40 pm | Live Presenter Q&A

Jacque Duncan
Professor, Clinical Ophthalmology
University of California, San Francisco

Day One

Wednesday, October 28, 2020

5:40 pm | Live Presenter Q&A

5:00 pm | Imaging in Dry Age-related Macular Degeneration

Amir Kashani
Associate Professor of Ophthalmology (Clinical Scholar)
University of Southern California

Day One

Wednesday, October 28, 2020

5:40 pm | Live Presenter Q&A

5:20 pm | Clinical Implementation of an Ultrathin Stem-Cell Derived RPE Monolayer in Phase 1/2a Clinical Trial for Treatment of Advanced Dry AMD with Geographic Atrophy

David Schaffer
Co-Founder, Chief Scientific Officer & Co-Chairman of The Board of Directors
4D Molecular Therapeutics

Day Two

Thursday, October 29, 2020

9:40 am | Live Presenter Q&A

9:20 am | "AAV Engineering for Retina Diseases in Mouse, Dog, and NHP”

Ulrich Luhmann
Biomarker Experimental Medicine Leader, Early Clinical Development
Roche

Day One

Wednesday, October 28, 2020

5:40 pm | Live Presenter Q&A

4:20 pm | Current Efforts to Evaluate Functional Visual Impairment and Clinically Relevant Endpoint Candidates for Intermediate Dry AMD

Irene Wang
Chief Operating Officer
Belite Bio

Day Two

Thursday, October 29, 2020

1:40 pm | Live Presenter Q&A

1:20 pm | Antagonism of Retinal Binding Protein 4 as a Therapeutic Strategy for Dry AMD Treatment